Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accutane Scripts Would Be Limited To Approved Indication Under House Bill

Executive Summary

Prescriptions for Roche's Accutane would be limited to the acne drug's approved indication under legislation introduced June 16 by Reps. Bart Stupak (D-Mich.) and Chris Smith (R-N.J.)

You may also be interested in...



Allergan Tazoral Turned Down By FDA Cmte.: Off-Label Acne Use Is Concern

Concerns about potential off-label use of Allergan's Tazoral as acne therapy figured heavily in an FDA advisory committee's recommendation against approving the retinoid drug for the treatment of moderate to severe psoriasis

Allergan Tazoral Turned Down By FDA Cmte.: Off-Label Acne Use Is Concern

Concerns about potential off-label use of Allergan's Tazoral as acne therapy figured heavily in an FDA advisory committee's recommendation against approving the retinoid drug for the treatment of moderate to severe psoriasis

Accutane Legislation Planned; Rep. Stupak Wants Mandatory Registries

Rep. Bart Stupak (D-Mich.) is drafting legislation to mandate patient and prescriber registries for the acne drug Accutane

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel